Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
A shareholder filed a Rule 144 notice to sell 7,310 shares of common stock, with an aggregate market value of 234,799.04, through Morgan Stanley Smith Barney on or about 02/03/2026 on the NASDAQ. These shares were acquired via restricted stock unit vesting on 01/31/2026 as compensation from the issuer. The filing also notes that the seller, Peter Heerma, sold 4,980 common shares for gross proceeds of 199,200 on 12/24/2025. Shares outstanding were 89,472,327 common shares at the time referenced, which is a baseline figure and not the amount being sold.
Sandra Calvin has filed a Rule 144 notice to sell 4,333 shares of TVTX common stock through Morgan Stanley Smith Barney on or about 02/03/2026 on NASDAQ, with an indicated aggregate market value of $139,177.16.
These shares were acquired on 01/31/2026 via restricted stock unit vesting from the issuer as compensation. The filing also lists prior sales over the past three months: 67,115 shares on 11/04/2025 for gross proceeds of $2,416,140.00, 2,910 shares on 12/15/2025 for $104,760.00, and 7,402 shares on 12/24/2025 for $296,080.00.
Christopher Cline filed notice of a planned sale of 7,242 shares of common stock of TVTX, with an aggregate market value of $232,616.03. The shares are to be sold on February 3, 2026 on the NASDAQ through Morgan Stanley Smith Barney.
The 7,242 shares were acquired on January 31, 2026 through restricted stock unit vesting from the issuer as compensation. Over the prior three months, Cline sold 20,000 common shares on December 1, 2025, generating $700,202.00 in gross proceeds.
TVTX insider Jula Inrig has filed a Form 144 indicating an intent to sell 6,956 shares of common stock through Morgan Stanley Smith Barney on or about 02/03/2026 on the NASDAQ, with an aggregate market value of $223,429.38. The shares were acquired on 01/31/2026 via restricted stock unit vesting from the issuer as compensation.
Over the prior three months, Jula Inrig sold additional common shares in three transactions: 445 shares for $16,798.75, 2,031 shares for $81,605.58, and 15,000 shares for $630,004.50. The filing also notes a representation that the seller is not aware of undisclosed material adverse information about the issuer.
Travere Therapeutics CEO Eric M. Dube reported multiple equity transactions. On January 31, 2026, he acquired 113,800 shares of common stock at $0 through restricted stock units and received an option for 303,600 shares at an exercise price of $33.095 per share.
On February 3, 2026, he sold 66,452 shares at $32.06 and 33,635 shares at $32.70 under a pre-arranged Rule 10b5-1 trading plan, which also covered tax obligations from vesting. After these transactions, he directly held 432,886 common shares and 303,600 stock options.
Travere Therapeutics’ chief medical officer, Jula Inrig, reported equity grants and a tax-related share sale. On 01/31/2026, she acquired 28,130 shares of common stock at $0 through restricted stock unit settlement, bringing her holdings to 114,441 shares before a later sale.
That same day she received an employee stock option for 75,000 shares of common stock at an exercise price of $33.095, expiring on 01/31/2036, with vesting over four years. On 02/03/2026, she sold 6,956 shares of common stock at $32.12 per share to cover tax withholding from the vested units, a mandated “sell to cover” transaction, not a discretionary trade. After the sale, she directly owned 107,485 common shares and 75,000 stock options.
Travere Therapeutics' Chief Financial Officer Christopher R. Cline reported equity compensation activity and a related share sale. On January 31, 2026, he acquired 28,130 shares of common stock for $0 upon settlement of restricted stock units and held 120,213 shares afterward.
That same day he received an employee stock option for 75,000 shares at an exercise price of $33.095, expiring on January 31, 2036, with one-fourth vesting after one year and the rest vesting in 36 monthly installments. On February 3, 2026, he sold 7,242 shares at $32.12 per share to cover tax withholding from the vested restricted stock units, leaving him with 112,971 directly owned shares; the filing notes this was a mandated “sell to cover” transaction, not a discretionary trade.
Travere Therapeutics, Inc. Chief Commercial Officer Peter Heerma reported equity transactions in company stock. On January 31, 2026, he acquired 26,120 shares of common stock at $0 per share in connection with restricted stock units, bringing his direct holdings to 139,133 shares.
That same day, he received an employee stock option grant for 69,640 shares at an exercise price of $33.095 per share, vesting over four years. On February 3, 2026, he sold 7,310 shares at $32.12 per share to cover tax withholding owed on vested restricted stock units. The sale was executed under a mandatory "sell to cover" arrangement and is not described as a discretionary trade. After this sale, he directly held 131,823 shares of Travere common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported routine equity compensation and a planned share sale. On 01/31/2026 he acquired 20,090 shares of common stock for $0 through restricted stock units and received an employee stock option for 53,570 shares at an exercise price of $33.095 per share.
These options vest over time, with one-fourth vesting on the first anniversary of grant and the remainder in 36 monthly installments. On 02/03/2026 he sold 12,446 shares of common stock at $32.87 per share under a Rule 10b5-1 trading plan, and held 109,087 common shares and 53,570 options directly afterward.